A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Vitiligo

In brief

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. This study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it. All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home. Participants may receive the study medicine or placebo for up to 52 weeks. The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo. Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study. Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.

Key facts

Study ID

NCT06163326

Run by

Pfizer

People needed

394

Starts

2024-01-19

Expected to finish

2027-03-31

Last updated by the study team

2026-04-29

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to <18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
• Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
• The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040

You may not qualify if…

• Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
• Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation

Where it is running

• Marvel Clinical Research — Huntington Beach, California, United States
• Wallace Medical Group, Inc — Los Angeles, California, United States
• Encore Medical Research of Boynton Beach — Boynton Beach, Florida, United States
• Skin Care Research — Hollywood, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
• DelRicht Research — Baton Rouge, Louisiana, United States
• Lawrence J. Green, MD LLC — Rockville, Maryland, United States
• University of Michigan — Ann Arbor, Michigan, United States
• University of New Mexico Health Sciences Center — Albuquerque, New Mexico, United States
• SUNY Downstate Health Sciences University — Brooklyn, New York, United States
• University of North Carolina Medical Center — Chapel Hill, North Carolina, United States
• Clinical & Translational Research Center (CTRC) — Chapel Hill, North Carolina, United States
• Accellacare - Wilmington — Wilmington, North Carolina, United States
• Wilmington Health, PLLC — Wilmington, North Carolina, United States
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
• Remington-Davis, Inc — Columbus, Ohio, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Modern Research Associates, PLLC — Dallas, Texas, United States
• Alpesh D. Desai, DO PLLC — Houston, Texas, United States
• Austin Institute for Clinical Research — Houston, Texas, United States
• The Skin Hospital — Darlinghurst, New South Wales, Australia
• North Eastern Health Specialists — Campbelltown, South Australia, Australia
• Skin Health Institute Inc. — Carlton, Victoria, Australia
• California Dermatology & Clinical Research Institute — Encinitas, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.